Today's Date: March 19, 2024
Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems   •   NATURE'S MIRACLE HOLDING INC. RECENTLY RANG THE CLOSING BELL AT NASDAQ, TIMES SQUARE NYC   •   RepRisk ESG risk data now available to Bloomberg Data Management Services customers   •   College of Saint Mary Selects YuJa Enterprise Video Platform as Campuswide Media Creation and Distribution Solution   •   Mitsubishi Electric Named to CDP Supplier Engagement Leader   •   TM Associates Announces Grand Opening of Luxury Affordable Apartment Community in DC, MDXL Flats Apartments   •   EverWind Fuels Praises Historic Canada-Germany Agreement to Sell Canadian Green Hydrogen   •   EarthX to Feature Benji Backer, Author of "The Conservative Environmentalist," at Upcoming Congress of Conferences   •   Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant   •   Smarter AI for All: Lenovo Unveils Hybrid AI Solutions that Deliver the Power of Tailored Generative AI to Every Enterprise and   •   Using Banuba SDKs Gives Businesses an Advantage in the Case of TikTok Ban   •   Mbanq and The Financial Policy Council to Host: “Business Banking Battles – Big Value in the Face of Bank Industry T   •   NAREB PREPARES MEMBERS FOR MAJOR CHANGES TO HOME SALES AGENT COMMISSIONS AFTER LAWSUIT SETTLEMENT   •   Statement by Minister Qualtrough on the Closing of the 2024 Arctic Winter Games in the Mat-Su Valley, Alaska   •   Spire Global to Enhance AI-Driven Weather Prediction in Collaboration with NVIDIA   •   SBS TO RECEIVE MULTIMILLION DOLLAR SETTLEMENT FROM VOZ MEDIA   •   Back Market Plugs into Google Cloud to Power Global Expansion and Support Sustainability Mission   •   UL Solutions and SINAI Technologies Join Forces to Help Customers Enhance Decarbonization and ESG Performance and Reporting   •   Cadence and NVIDIA Unveil Groundbreaking Generative AI and Accelerated Compute-Driven Innovations   •   New ASEAN Energy and ACTUAL Sign Cooperation Agreement to Develop Net-Zero Plan for the New $5B USD Pengerang Energy Complex
Bookmark and Share

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) I

NEW YORK , February 01 /Businesswire/ - The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs”) (NASDAQ: YMAB) securities during the period from October 6, 2020 through October 28, 2022 (the “Class Period”). Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Y-mAbs operates as a clinical-stage biopharmaceutical company, with headquarters in New York, NY.

On March 31, 2022, Y-mAbs announced it completed the resubmission of its Biologics License Application (“BLA”) for omburtamab to the Food and Drug Administration (“FDA”). The action alleges that throughout the Class Period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, that progress was being made that would align with the FDA's requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab. What was unknown to investors was that the FDA had repeatedly advised Y-mAbs that the treatment of effect of omburtamab cannot be objectively established or quantified based on a comparison between Study 03-133 and an external cohort comprised of data from the Central German Childhood Cancer Registry (“CGCCR”) database because of substantial differences in the patient populations, and the absence of tumor response data, and that Study 101 was neither sufficiently advanced nor indicative of efficacy to justify approval. Further, Y-mAbs failed to advise investors that it had elected to submit the March 31, 2022 BLA prior to reaching agreement with the FDA on the content of the application. The truth was revealed early in the trading day on October 26, 2022 when the FDA publicly released its Briefing Document for the Oncologic Drugs Advisory Committee (“ODAC”).

On October 26, 2022, the FDA publicly released its Briefing Document for the Advisory Committee Meeting, in which it identified three key issues in the application submitted by Y-mAbs and brought to light Y-mAbs’s election to resubmit the BLA on March 31, 2022 prior to reaching agreement with the FDA on the content of the application. The Briefing Document stated that the FDA had allegedly repeatedly raised its concerns to the defendants in prior communications and meetings such as the pre-BLA Type B meeting on January 13, 2022. On this news, the price of Y-mAbs shares declined by $4.16 per share, or approximately 27.42%, from $15.17 per share to close at $11.01 on October 26, 2022. The price then declined again by $2.16 per share, or approximately 19.62%, from $11.01 per share to close at $8.85 on October 27, 2022.

On October 28, 2022, Y-mAbs filed a Form 8-K with the SEC, which informed investors that the advisory committee had voted 16 to 0 that Y-mAbs had not provided sufficient evidence to conclude that Omburtamab improved overall survival. The grounds for denial were precisely the same grounds that Y-mAbs was apprised of by the FDA during their 2020 bid for BLA approval. On this news, the price of Y-mAbs shares declined by $5.32 per share, or approximately 59.57%, from $8.93 per share to close at $3.61 on October 31, 2022.

If you purchased or otherwise acquired Y-mAbs securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


STORY TAGS: Class Action Lawsuit, Professional Services, Legal, Lawsuit, New York, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News